Literature DB >> 9916468

Infection of an intravenous port system with Metschnikowia pulcherrima Pitt et Miller.

W Mohl1, M M Lerch, M Klotz, H Freidank, M Zeitz.   

Abstract

A patient with short bowel syndrome as a consequence of multiple intestinal resections for Crohn's disease, had a port system implanted to improve her nutritional status. One year later she presented with fever, weakness and nighttime sweating. Metschnikowia pulcherrima Pitt et Miller was grown in blood cultures from the port system. After antifungal chemotherapy using fluconazole and removal of the implant, the patient's condition improved markedly and her fever and sweating disappeared. We conclude that Metschnikowia pulcherrima can turn into a human pathogen in patients with indwelling catheters for parenteral nutrition. Chemotherapy with fluconazole and, whenever possible, removal of the implant, appear to be adequate treatment.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9916468     DOI: 10.1111/j.1439-0507.1998.tb00365.x

Source DB:  PubMed          Journal:  Mycoses        ISSN: 0933-7407            Impact factor:   4.377


  3 in total

Review 1.  Significance of CXCL12 in type 2 diabetes mellitus and its associated complications.

Authors:  Mojgan Noroozi Karimabad; Gholamhossein Hassanshahi
Journal:  Inflammation       Date:  2015-04       Impact factor: 4.092

2.  Isolation and Characterization of an Atypical Metschnikowia sp. Strain from the Skin Scraping of a Dermatitis Patient.

Authors:  Chee Sian Kuan; Rokiah Ismail; Zhenli Kwan; Su Mei Yew; Siok Koon Yeo; Chai Ling Chan; Yue Fen Toh; Shiang Ling Na; Kok Wei Lee; Chee-Choong Hoh; Wai-Yan Yee; Kee Peng Ng
Journal:  PLoS One       Date:  2016-06-09       Impact factor: 3.240

3.  Community acquired fungemia caused by Candida pulcherrima: diagnostic contribution of MALDI-TOF mass spectrometry.

Authors:  Laurène Deconinck; Agnès Meybeck; Maxime Pradier; Pierre Patoz; Hugues Melliez; Eric Senneville
Journal:  Ann Clin Microbiol Antimicrob       Date:  2016-03-08       Impact factor: 3.944

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.